Farmmi Inc

Análisis de la acción Farmmi Inc (FAMI)

$0.093

+0.003 (+2.88%)Al cierre

Loading chart…
Máximo
0.098
Apertura
0.096
Precio medio ponderado por volumen
0.09
Volumen
2.14M
Capitalización
4.70M
Mínimo
0.092
Importe
201.19K
EV/EBITDA, TTM
0.00

Farmmi Inc is a holding company principally engaged in the processing and sales of a variety of mushrooms, edible fungi and other agricultural products. The Company’s main products include edible fungi (edible mushroom), shiitake, Mu Er, bamboo fungi, agrocybe aegerila, pleurotus eryngii, grifola frondosa and other agricultural products such as crab, orange, rice and others. The Company distributes products under brand Lishui Shangeng, Farmmi Liangpin, Forasen, and others. The Company distributes products in the domestic and overseas markets, including the U.S., Japan, Canada, and other countries or regions.

farmmi.com

Análisis de IA of Farmmi Inc (FAMI)

Vender

Farmmi Inc is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has a current price of $0.09, which is near its 52-week low of $0.09, and it has experienced a staggering year-to-date change of -92.79%. Additionally, the company's forward P/E ratio is 0, indicating no expected earnings growth, and it recently completed a public offering at a 79% discount, which has raised concerns about its financial health. The main risk is the company's substantial net loss of $53.4 million for the fiscal year ending September 30, 2025, alongside a revenue decline of over 56%.

Métricas de valoración

El PER previsto actual de Farmmi Inc (FAMI) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para FAMI

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%FAMI

$1.91

Precio del escenario

B

Base

Base · 50%FAMI

$1.68

Precio del escenario

B

Bajista

Bajista · 25%FAMI

$1.45

Precio del escenario

Cronología de eventos

2026-08-04 (ET)

17:30:00

Farmmi Signs Acquisition Agreement to Acquire 100% Equity of Four Seasons Holding Group

2026-06-29 (ET)

08:00:00

Farmmi Prices Public Offering Expected to Raise $3M

2026-03-11 (ET)

07:10:00

Farmmi Subsidiary Receives Hazardous Materials Permit in California

2026-01-26 (ET)

07:10:00

Farmmi Establishes Wholly-Owned Subsidiary Bluesage Marketing for Digital Marketing

2026-01-14 (ET)

07:10:00

Farmmi Subsidiary Achieves FDA Food Facility Registration

Noticias

Preguntas frecuentes sobre FAMI, respondidas por Alphio AI

Farmmi Inc is a holding company principally engaged in the processing and sales of a variety of mushrooms, edible fungi and other agricultural products. The Company’s main products include edible fungi (edible mushroom), shiitake, Mu Er, bamboo fungi, agrocybe aegerila, pleurotus eryngii, grifola frondosa and other agricultural products such as crab, orange, rice and others. The Company distributes products under brand Lishui Shangeng, Farmmi Liangpin, Forasen, and others. The Company distributes products in the domestic and overseas markets, including the U.S., Japan, Canada, and other countries or regions. It operates in the Consumer Non-Cyclicals sector (CANNED FRUITS, VEGETABLES, PRESERVES, JAMS, AND JE industry).

Farmmi Inc is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has a current price of $0.09, which is near its 52-week low of $0.09, and it has experienced a staggering year-to-date change of -92.79%. Additionally, the company's forward P/E ratio is 0, indicating no expected earnings growth, and it recently completed a public offering at a 79% discount, which has raised concerns about its financial health. The main risk is the company's substantial net loss of $53.4 million for the fiscal year ending September 30, 2025, alongside a revenue decline of over 56%.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar